SCHEMBL4552749

SCHEMBL4552749

COc1cccc2c1ccc1c3ccccc3cnc21

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NQO2 P16083 3/20 0.46
▸ HPGDS O60760 2/20 0.44
▸ NQO1 P15559 1/20 0.43
▸ KDM4E B2RXH2 1/20 0.43
▸ GPR3 P46089 1/20 0.43
▸ MAPT P10636 2/20 0.42
▸ GABRP O00591 1/20 0.42
▸ GABRD O14764 1/20 0.42
▸ GABRA1 P14867 1/20 0.42
▸ GABRB1 P18505 1/20 0.42
▸ GABRG2 P18507 1/20 0.42
▸ GABRB3 P28472 1/20 0.42
▸ GABRA5 P31644 1/20 0.42
▸ GABRA3 P34903 1/20 0.42
▸ GABRA2 P47869 1/20 0.42
▸ GABRB2 P47870 1/20 0.42
▸ GABRA4 P48169 1/20 0.42
▸ GABRE P78334 1/20 0.42
▸ GABRA6 Q16445 1/20 0.42
▸ GABRG1 Q8N1C3 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12463180 0.90 HPGDS (0.54) NQO2HPGDSKDM4EGPR3ATP4A
SCHEMBL1005616 0.78 MAPT (0.59) NQO2NQO1KDM4EMAPTIDO1
SCHEMBL19748987 0.78 KDM4E (0.60) KDM4EGPR3MAPTPDPK1PLAU
SCHEMBL14871760 0.77 HTR1A (0.53) PLAU
SCHEMBL1649420 0.77 NQO2 (0.69) NQO2KDM4EMAPTGRM5KCNH2
SCHEMBL241747 0.76 HPRT1 (0.54) KDM4EGPR3MAPT
SCHEMBL30956235 0.76 HPRT1 (0.61) KDM4EGPR3MAPT
Hydrochloric Acid SCHEMBL3322796 0.74 HPRT1 (0.52) KDM4EGPR3MAPT
SCHEMBL29367279 0.73 MAPT (0.61) NQO1KDM4EMAPTIDO1
SCHEMBL30373629 0.73 MAPT (0.61) NQO1KDM4EMAPTIDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2099442-A1 METHOD OF USING HISTONE DEACETYLASE INHIBITORS AND MONITORING BIOMARKERS IN COMBINATION THERAPY PHARMACYCLICS, INC. (US) 2009-09-16 — — EP disclosed
WO-2008082856-A1 METHOD OF USING HISTONE DEACETYLASE INHIBITORS AND MONITORING BIOMARKERS IN COMBINATION THERAPY PHARMACYCLICS, INC. (US) 2008-07-10 — — WO disclosed
WO-2007139585-A1 CONTROLLED-RELEASE FORMULATION SCHERING CORPORATION (US) 2007-12-06 — — WO disclosed
Send feedback